glp-1 cv outcome trials Beyond GLP1: modulating multiple nutrient-stimulated hormone pathways to reduce cardiovascular risk Tirzepatide linked to lower risk

Accessed 12 Nov 2021

Oral GLP-1s can produce an average weight loss of ~6%14%, depending on the medication: Rybelsus (semaglutide) produces nearly 6% weight loss in one year , according to a small study of adults with obesity

Use the powerful tools we have available today Tirzepatide or Semaglutide to do the heavy lifting

Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD randomized clinical trial

Tirzepatide works on two receptors (GLP-1 and GIP)

Raghavendra Tirupathi, and medical students studying under him, Shruti Vadali, Shanthi Reddy and Avinash Javajji, discuss how these medications work, who may be a good candidate, and more